ENDRA Life Sciences (NDRA) Free Cash Flow (2016 - 2026)

ENDRA Life Sciences has disclosed Free Cash Flow across 11 years of filings, most recently posting -$1.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 14.56% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$5.0 million (up 23.59% YoY), while the FY2025 annual figure was -$5.2 million, up 29.89% from the prior year.
• Free Cash Flow climbed to -$1.1 million in Q1 2026, from -$1.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for NDRA reached as high as -$1.1 million in Q2 2025 and fell as low as -$3.4 million in Q2 2022.
• The 5-year median for Free Cash Flow is -$2.2 million (2024), against an average of -$2.1 million.
• Annual changes were most pronounced in 2022 — Free Cash Flow decreased 21.27% — and 2025, when it surged 46.26%.
• A 5-year view of Free Cash Flow shows it stood at -$3.1 million in 2022, then jumped by 30.24% to -$2.2 million in 2023, then jumped by 30.52% to -$1.5 million in 2024, then retreated by 6.33% to -$1.6 million in 2025, then jumped by 30.53% to -$1.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$1.1 million, -$1.6 million, and -$1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.